JCO Early Release, published online ahead of print May 7 2007
Journal of Clinical Oncology, 10.1200/JCO.2006.09.3260
Received September 26, 2006
Accepted March 19, 2007
Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Silvia Montoto,* Andrew John Davies, Janet Matthews, Maria Calaminici, Andrew J. Norton, John Amess, Sarah Vinnicombe, Rachel Waters, Ama Z.S. Rohatiner, and T. Andrew Lister
From the Cancer Research UK Medical Oncology Unit, Barts and the London, Queen Mary's School of Medicine and Dentistry; Departments of Cellular Pathology, Haematology, and Radiology, Barts and the London NHS Trust, London; and the Cancer Research UK Medical Statistics Group, University of Oxford, Oxford, United Kingdom.
* To whom correspondence should be addressed. E-mail: silvia.montoto{at}cancer.org.uk
Purpose: To study the clinical significance of transformation to diffuse large B-cell lymphoma (DLBCL) in patients with follicular lymphoma (FL).
Patients and Methods: From 1972 to 1999, 325 patients were diagnosed with FL at St Bartholomew's Hospital (London, United Kingdom). With a median follow-up of 15 years, progression occurred in 186 patients and biopsy-proven transformation in 88 of the 325. The overall repeat biopsy rate was 70%.
Results: The risk of histologic transformation (HT) by 10 years was 28%, HT not yet having been observed after 16.2 years. The risk was higher in patients with advanced stage (P = .02), high-risk Follicular Lymphoma International Prognostic Index (FLIPI; P = .01), and International Prognostic Index (IPI; P = .04) scores at diagnosis. Expectant management (as opposed to treatment being initiated at diagnosis) also predicted for a higher risk of HT (P = .008). Older age (P = .005), low hemoglobin level (P = .03), high lactate dehydrogenase (P < .0001), and high-risk FLIPI (P = .01) or IPI (P = .003) score at the time of first recurrence were associated with the diagnosis of HT in a biopsy performed at that time. The median survival from transformation was 1.2 years. Patients with HT had a shorter overall survival (P < .0001) and a shorter survival from progression (P < .0001) than did those in whom it was not diagnosed.
Conclusion: Advanced stage and high-risk FLIPI and IPI scores at diagnosis correlate with an increased risk of HT. This event strongly influences the outcome of patients with FL by shortening their survival. There may be a subgroup of patients in whom HT does not occur.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. A. Martinez-Climent, L. Fontan, R. D. Gascoyne, R. Siebert, and F. Prosper
Lymphoma stem cells: enough evidence to support their existence?
Haematologica,
February 1, 2010;
95(2):
293 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Oschlies, I. Salaverria, F. Mahn, A. Meinhardt, M. Zimmermann, W. Woessmann, B. Burkhardt, S. Gesk, M. Krams, A. Reiter, et al.
Pediatric follicular lymphoma - a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma - Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials
Haematologica,
February 1, 2010;
95(2):
253 - 259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Gentles, A. A. Alizadeh, S.-I. Lee, J. H. Myklebust, C. M. Shachaf, B. Shahbaba, R. Levy, D. Koller, and S. K. Plevritis
A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients
Blood,
October 8, 2009;
114(15):
3158 - 3166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye
Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence
Oncologist,
October 1, 2009;
14(suppl_2):
17 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Carlotti, D. Wrench, J. Matthews, S. Iqbal, A. Davies, A. Norton, J. Hart, R. Lai, S. Montoto, J. G. Gribben, et al.
Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone
Blood,
April 9, 2009;
113(15):
3553 - 3557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Friedberg, M. D. Taylor, J. R. Cerhan, C. R. Flowers, H. Dillon, C. M. Farber, E. S. Rogers, J. D. Hainsworth, E. K. Wong, J. M. Vose, et al.
Follicular Lymphoma in the United States: First Report of the National LymphoCare Study
J. Clin. Oncol.,
March 10, 2009;
27(8):
1202 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O'Shea, C. O'Riain, M. Gupta, R. Waters, Y. Yang, D. Wrench, J. Gribben, A. Rosenwald, G. Ott, L. M. Rimsza, et al.
Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation
Blood,
March 5, 2009;
113(10):
2298 - 2301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Bernstein and W. R. Burack
The incidence, natural history, biology, and treatment of transformed lymphomas
Hematology,
January 1, 2009;
2009(1):
532 - 541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Luthy, A. K. Ng, B. Silver, K. O. Degnan, D. C. Fisher, A. S. Freedman, and P. M. Mauch
Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma
Ann. Onc.,
December 1, 2008;
19(12):
2043 - 2047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin,
September 1, 2008;
58(5):
305 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Johnson and R. D. Gascoyne
Gene expression signatures in follicular lymphoma: are they ready for the clinic?
Haematologica,
July 1, 2008;
93(7):
982 - 987.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
